Trial reportBMC cancer2014
INTRAGO: intraoperative radiotherapy in glioblastoma multiforme—a phase I/II dose escalation study.
Trial report in BMC cancer, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to 2 registered trials, which are not on this map. Cited by 28 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
INTRAGO-Intraoperative Radiotherapy for Glioblastoma - a Phase I/II Study
A Multicenter Randomized Phase III Trial on INTraoperative RAdiotherapy in Newly Diagnosed GliOblastoma Multiforme (INTRAGO II)
Who cites it
28 citing papers in PubMed, 53 citations in OpenAlex.
- Targeting tumour-neuron synapses with intracavitary RNA delivery prevents glioblastoma recurrence.Nature biomedical engineering · 2026Article
- Cognitive Impairment in Patients with Glioma: Mechanisms, Assessment, and Emerging Therapeutic Strategies.Cancers · 2026Review
- Comparing intraoperative radiotherapy (IORT) and hypofractionated stereotactic radiotherapy (HSRT) after brain metastasis surgery: impact on oncological outcome and radionecrosis.Journal of neuro-oncology · 2025Article
- Emerging Technologies in Radiation Therapy: Replacing Traditional Isotope-based Modalities.Health physics · 2025Review
- Evaluation of the TG-43 formalism for intraoperative radiotherapy dosimetry in glioblastoma treatment.Medical physics · 2025Article
- EZH2 inhibition and 5-azacytidine enhance antitumor immunity in PTEN-deficient glioblastoma by activation viral mimicry response.Journal for immunotherapy of cancer · 2025Article
- Cognitive Decline in Glioblastoma (GB) Patients with Different Treatment Modalities and Insights on Untreated Cases.Current oncology (Toronto, Ont.) · 2025Review
- Article
- Innovations in intraoperative therapies in neurosurgical oncology: a narrative review.Journal of neuro-oncology · 2025Review
- A prospective observational study of inflammatory mediators in cerebrospinal fluid after intraoperative radiotherapy of brain tumors.Therapeutic advances in medical oncology · 2025Article
- Intraoperative glioblastoma surgery-current challenges and clinical trials: An update.Cancer pathogenesis and therapy · 2024Review
- Intraoperative radiotherapy after neurosurgical resection of brain metastases as institutional standard treatment- update of the oncological outcome form a single center cohort after 117 procedures.Journal of neuro-oncology · 2024Article
- Metabolism/Immunity Dual-Regulation Thermogels Potentiating Immunotherapy of Glioblastoma Through Lactate-Excretion Inhibition and PD-1/PD-L1 Blockade.Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2024Article
- Intracranial intraoperative radiotherapy (IORT): evaluation of electrocorticography and peri-operative seizure risk.Journal of neuro-oncology · 2023Article
- Surgical Treatment of Glioblastoma: State-of-the-Art and Future Trends.Journal of clinical medicine · 2022Review
- Tumor-associated alterations in white matter connectivity have prognostic significance in MGMT-unmethylated glioblastoma.Journal of neuro-oncology · 2022Article
- Intraoperative radiotherapy with low-energy x-rays after neurosurgical resection of brain metastases-an Augsburg University Medical Center experience.Strahlentherapie und Onkologie : Organ der Deutschen Rontgengesellschaft ... [et al] · 2021Article
- Drug repurposing using transcriptome sequencing and virtual drug screening in a patient with glioblastoma.Investigational new drugs · 2021Article
- Intraoperative Radiotherapy in Brain Malignancies: Indications and Outcomes in Primary and Metastatic Brain Tumors.Frontiers in oncology · 2021Review
- Intrabeam Radiation Inhibits Proliferation, Migration, and Invasiveness and Promotes Apoptosis of MCF-7 Breast Cancer Cells.Technology in cancer research & treatment · 2019Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors at 3 institutions in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundGlioblastoma multiforme (GBM) is the most frequent primary malignant brain tumor in adults. Despite multimodal therapies, almost all GBM recur within a narrow margin around the initial resected lesion. Thus, novel therapeutic intensification strategies must target both, the population of dispersed tumor cells around the cavity and the postoperative microenvironment. Intraoperative radiotherapy (IORT) is a pragmatic and effective approach to sterilize the margins from persistent tumor cells, abrogate post-injury proliferative stimuli and to bridge the therapeutic gap between surgery and radiochemotherapy. Therefore, we have set up INTRAGO, a phase I/II dose-escalation study to evaluate the safety and tolerability of IORT added to standard therapy in newly diagnosed GBM. In contrast to previous approaches, the study involves the application of isotropic low-energy (kV) x-rays delivered by spherical applicators, providing optimal irradiation properties to the resection cavity. METHODS/
designINTRAGO includes patients aged 50 years or older with a Karnofsky performance status of at least 50% and a histologically confirmed (frozen sections) supratentorial GBM. Safety and tolerability (i.e., the maximum tolerated dose, MTD) will be assessed using a classical 3 + 3 dose-escalation design. Dose-limiting toxicities (DLT) are wound healing deficits or infections requiring surgical intervention, IORT-related cerebral bleeding or ischemia, symptomatic brain necrosis requiring surgical intervention and early termination of external beam radiotherapy (before the envisaged dose of 60 Gy) due to radiotoxicity. Secondary end points are progression-free and overall survival.
trial registrationThe study is registered with clinicaltrials.gov, number: NCT02104882 (Registration Date: 03/26/2014).
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.